These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 26347001)

  • 21. Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab.
    Dominguez-Mozo MI; Garcia-Montojo M; De Las Heras V; Garcia-Martinez A; Arias-Leal AM; Casanova I; Arroyo R; Alvarez-Lafuente R
    J Neuroimmune Pharmacol; 2013 Dec; 8(5):1277-86. PubMed ID: 23979860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A longitudinal study of JC virus serostatus stability among multiple sclerosis patients.
    Alroughani R; Akhtar S; Ahmed S; Al-Hashel J
    Mult Scler Relat Disord; 2018 Feb; 20():132-135. PubMed ID: 29414286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain.
    Aladro Y; Terrero R; Cerezo M; Ginestal R; Ayuso L; Meca-Lallana V; Millán J; Borrego L; Martinez-Ginés M; Rubio L; de Andrés C; Miralles A; Guijarro C; Rodríguez-García E; García-Dominguez JM; Muñoz-Fernández C; López de Silanes C; Gómez M; Thuissard I; Cerdán M; Palmí I; Díaz-Garzón LF; Meca-Lallana J
    J Neurol Sci; 2016 Jun; 365():16-21. PubMed ID: 27206867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.
    Achiron A; Miron G; Zilkha-Falb R; Magalashvili D; Dolev M; Stern Y; Gurevich M
    J Neurovirol; 2016 Dec; 22(6):736-746. PubMed ID: 27170332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
    Schweitzer F; Ladwig A; Opala S; Laurent S; Schroeter M; Goelz S; Fink GR; Wieland U; Silling S; Warnke C
    Mult Scler Relat Disord; 2024 Jul; 87():105664. PubMed ID: 38735204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between anti-JC-virus and anti-cytomegalovirus, -Epstein-Barr virus and -measles/-rubella/-varicella-zoster-virus antibodies.
    Auer M; Borena W; Holm-von Laer D; Deisenhammer F
    J Med Virol; 2017 Jan; 89(1):3-9. PubMed ID: 27253624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
    Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
    Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PML risk stratification using anti-JCV antibody index and L-selectin.
    Schwab N; Schneider-Hohendorf T; Pignolet B; Spadaro M; Görlich D; Meinl I; Windhagen S; Tackenberg B; Breuer J; Cantó E; Kümpfel T; Hohlfeld R; Siffrin V; Luessi F; Posevitz-Fejfár A; Montalban X; Meuth SG; Zipp F; Gold R; Du Pasquier RA; Kleinschnitz C; Jacobi A; Comabella M; Bertolotto A; Brassat D; Wiendl H
    Mult Scler; 2016 Jul; 22(8):1048-60. PubMed ID: 26432858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.
    van Kempen ZLE; Leurs CE; de Vries A; Vennegoor A; Rispens T; Wattjes MP; Killestein J
    Eur J Neurol; 2017 Sep; 24(9):1196-1199. PubMed ID: 28707781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JCV serology in time: 3 years of follow-up.
    Cambron M; Hadhoum N; Duhin E; Lacour A; Chouraki A; Vermersch P
    Acta Neurol Scand; 2017 Jul; 136(1):54-58. PubMed ID: 27766611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Bacchetta F; Mathias A; Schluep M; Du Pasquier R
    Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? No.
    Labauge P
    Rev Neurol (Paris); 2017 Dec; 173(10):614-615. PubMed ID: 29102328
    [No Abstract]   [Full Text] [Related]  

  • 34. Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? Comments. Anti-JCV antibody index in multiple sclerosis care.
    Stankoff B
    Rev Neurol (Paris); 2017 Dec; 173(10):616-618. PubMed ID: 29128153
    [No Abstract]   [Full Text] [Related]  

  • 35. JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.
    Delbue S; Elia F; Carloni C; Pecchenini V; Franciotta D; Gastaldi M; Colombo E; Signorini L; Carluccio S; Bellizzi A; Bergamaschi R; Ferrante P
    J Neurovirol; 2015 Dec; 21(6):645-52. PubMed ID: 25052191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? YES.
    Wiertlewski S
    Rev Neurol (Paris); 2017 Dec; 173(10):610-613. PubMed ID: 28760447
    [No Abstract]   [Full Text] [Related]  

  • 37. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age-Dependent Seroprevalence of JCV Antibody in Children.
    Hennes EM; Kornek B; Huppke P; Reindl M; Rostasy K; Berger T
    Neuropediatrics; 2016 Apr; 47(2):112-4. PubMed ID: 26479766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
    Schwab N; Schneider-Hohendorf T; Hoyt T; Gross CC; Meuth SG; Klotz L; Foley JF; Wiendl H
    Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
    Fragoso YD; Mendes MF; Arruda WO; Becker J; Brooks JB; Carvalho Mde J; Comini-Frota ER; Domingues RB; Ferreira ML; Finkelsztejn A; Gama PD; Gomes S; Gonçalves MV; Kaimen-Maciel DR; Morales Rde R; Muniz A; Ruocco HH; Salgado PR; Albuquerque LB; Gama RA; Georgeto S; Lopes J; Oliveira CL; Oliveira FT; Safanelli J; Saldanha PC; Satomi M
    Arq Neuropsiquiatr; 2013 Oct; 71(10):780-2. PubMed ID: 24212514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.